Elisa Agostinetto: It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab
Elisa Agostinetto, Research Physician at the Institute of Jules Bordet in Brussels, posted on X/Twitter:
“Free access to our editorial in Annals of Oncology at the link given below.
The role of adjuvant Pembrolizumab is unclear, as KEYNOTE-522 did not foresee a randomisation at surgery. It’s likely that adjuvant Pembrolizumab has a lower impact compared to neoadjuvant Pembrolizumab.”
Additional information.
Source: Elisa Agostinetto/X
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within a short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023